The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.

  title={The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.},
  author={Michelle L Mcdonald and J Kellogg Parsons},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  volume={13 12},
A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
7 Citations
59 References
Similar Papers


Publications referenced by this paper.
Showing 1-10 of 59 references

Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies

  • AW Partin, L Van Neste, EA Klein
  • J Urol 2014;192:1081–1087
  • 2014

Similar Papers

Loading similar papers…